Paladin Labs

Ampio Pharmaceuticals' Vyrix inks agreement with Paladin Labs

Monday, April 14, 2014 03:01 PM

Ampio Pharmaceuticals’ wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty pharma company focused on developing and commercializing late-stage prescription pharmaceuticals to improve men's sexual health, has signed an agreement with Paladin Labs, a Canadian specialty pharma company, to provide exclusive rights to market, sell and distribute Zertane in Canada, the Republic of South Africa, Sub-Saharan Africa and Latin America.

More... »

WIRB Copernicus Group

FDA approves Impavido to treat tropical disease leishmaniasis

Thursday, March 20, 2014 11:40 AM

The FDA has approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted to humans through sand fly bites. The disease occurs primarily in people who live in the tropics and subtropics. Most U.S. patients acquire leishmaniasis overseas.

More... »

CRF Health eCOA webinar series

Endo to acquire Paladin Labs

Wednesday, November 6, 2013 12:48 PM

Endo Health Solutions has reached a definitive agreement to acquire Paladin Labs, a Canada-based specialty pharmaceutical company, in a stock and cash transaction valued at approximately $1.6 billion, of which approximately 98% will be paid in stock. The acquisition accelerates Endo's strategic transformation to a global specialty healthcare company and creates a platform for future growth in North America and internationally. Each share of Endo and Paladin Labs will be acquired by a newly-formed Irish holding company (New Endo). At $77 per Paladin Labs share, the transaction represents a 20% premium to Paladin Labs' share price on Nov. 4.

More... »

QRxPharma inks strategic collaboration with Paladin Labs

Wednesday, October 10, 2012 11:31 AM

QRxPharma, a commercial-stage specialty pharmaceutical company based in Bedminster, N.J., signed a licensing agreement with Paladin Labs, specialty pharmaceutical company based in Montreal, for the Canadian commercialization rights to Moxduo, a patented, immediate-release formulation of morphine and oxycodone. 

More... »

Paladin partners with Litha, aid merge of South African pharmas

Thursday, February 23, 2012 06:30 AM

Montreal-based Paladin Labs has formed a strategic partnership to accelerate its buyout of the remaining shares of South Africa-based Pharmaplan and merge the business with the pharma division of Litha Healthcare Group, based in South Africa.

More... »

Valeant to acquire Afexa Life Sciences

Wednesday, August 31, 2011 12:25 PM

Valeant Pharmaceuticals International has agreed to acquire fellow Canadian firm Afexa Life Sciences for $76 million in cash, a figure that comfortably tops an offer made by another company based in Canada, Paladin Labs, according to PharmaTimes.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs